Celgene Corporation Stock Price, News & Analysis (NASDAQ:CELG)

$104.50 -0.66 (-0.63 %)
(As of 11/24/2017 04:24 AM ET)
Previous Close$105.16
Today's Range$104.34 - $105.79
52-Week Range$94.55 - $147.17
Volume2.52 million shs
Average Volume8.34 million shs
Market Capitalization$82.79 billion
P/E Ratio16.43
Dividend YieldN/A
Beta1.79

About Celgene Corporation (NASDAQ:CELG)

Celgene Corporation logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Debt-to-Equity Ratio1.31%
Current Ratio3.65%
Quick Ratio3.52%

Price-To-Earnings

Trailing P/E Ratio16.43
Forward P/E Ratio15.67
P/E Growth0.81

Sales & Book Value

Annual Sales$11.23 billion
Price / Sales7.33
Cash Flow$5.99 per share
Price / Cash17.46
Book Value$12.51 per share
Price / Book8.35

Profitability

Trailing EPS$4.21
Net Income$2.00 billion
Net Margins27.36%
Return on Equity63.80%
Return on Assets17.45%

Miscellaneous

Employees7,132
Outstanding Shares787,320,000

Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)

What is Celgene Corporation's stock symbol?

Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?

Celgene Corporation's stock split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.

How were Celgene Corporation's earnings last quarter?

Celgene Corporation (NASDAQ:CELG) announced its earnings results on Thursday, October, 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.87 by $0.04. The biopharmaceutical company earned $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $1.58 earnings per share. View Celgene Corporation's Earnings History.

When will Celgene Corporation make its next earnings announcement?

Celgene Corporation is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Celgene Corporation.

What guidance has Celgene Corporation issued on next quarter's earnings?

Celgene Corporation updated its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of $7.30-7.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.31. The company issued revenue guidance of $13 billion, compared to the consensus revenue estimate of $13.23 billion.

Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?

29 Wall Street analysts have issued 12-month target prices for Celgene Corporation's stock. Their forecasts range from $91.00 to $166.00. On average, they anticipate Celgene Corporation's stock price to reach $139.69 in the next twelve months. View Analyst Ratings for Celgene Corporation.

What are Wall Street analysts saying about Celgene Corporation stock?

Here are some recent quotes from research analysts about Celgene Corporation stock:

  • 1. Cann analysts commented, "We conducted a physician survey to evaluate the current treatment preferences and satisfaction with available therapies, along with expectations for therapies in clinical development. Our report (published 11/21/17), Multiple Sclerosis Survey: Unmet Need Persists Despite Several Approved Treatment Options, concluded that there is a meaningful unmet need in MS treatment and a high level of interest in Ozanimod if FDA-approved. We conclude that approximately 80% of the neurologists surveyed are unsatisfied with the therapies available to them. The survey showed that 40.4% of patients are being treated with oral therapy. The surveyed neurologists replied that they would, on average, put 23.8% of their patients on a newly approved therapy they had selected from the survey." (11/22/2017)
  • 2. Cantor Fitzgerald analysts commented, "SUNBEAM and RADIANCE Shine Bright. Both these studies (one year and two years, respectively), in our view, show ozanimod to be a competitive agent in the field, with statistically significant reductions in annualized relapse rate for both time intervals: 48% at one year and 38% at two years for the 1 mg dose." (10/30/2017)
  • 3. BTIG Research analysts commented, "After mkt-close on Thursday, Celgene announced termination of the Phase 3 studies (REVOLVE and SUSTAIN) for mongersen in the treatment of Crohn’s disease, and that the Phase 3 DEFINE study will not be initiated. Termination of the programs follow the recommendation of the Data Monitoring Committee (DMC) who indicated futility of mongersen in producing a clinical benefit. Based on the announcement, we have taken our 2023 mongersen estimates to zero from $215m previously, versus consensus at ~$1bn." (10/22/2017)
  • 4. According to Zacks Investment Research, "Celgene’s Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. The consecutive increase in annual earnings guidance is also a positive. Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. The approval of Idhifa in the U.S. for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. Moreover, shares of Celgene have outperformed the industry in the year so far. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue while Abraxane sales are under competitive pressure." (10/18/2017)

Who are some of Celgene Corporation's key competitors?

Who are Celgene Corporation's key executives?

Celgene Corporation's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board (Age 62)
  • Scott A. Smith, President, Chief Operating Officer (Age 55)
  • Mark J. Alles, Chief Executive Officer, Director (Age 58)
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President (Age 61)
  • Terrie Curran, President, Global Inflammation & Immunology Franchise (Age 48)
  • Michael F. Pehl, President, Hematology & Oncology (Age 52)
  • Rupert J. Vessey, President - Research and Early Development (Age 52)
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary (Age 49)
  • Michael D. Casey, Lead Independent Director (Age 71)
  • Michael W. Bonney, Director (Age 58)

Who owns Celgene Corporation stock?

Celgene Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Jennison Associates LLC (1.90%), Edgewood Management LLC (1.34%), Ameriprise Financial Inc. (1.21%), Bank of New York Mellon Corp (1.21%), Janus Henderson Group PLC (1.20%) and American Century Companies Inc. (0.83%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene Corporation.

Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?

Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Jackson Square Partners LLC, Ameriprise Financial Inc., ING Groep NV, Bank of New York Mellon Corp, USS Investment Management Ltd, Macquarie Group Ltd. and California State Teachers Retirement System. Company insiders that have sold Celgene Corporation company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene Corporation.

Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?

Celgene Corporation's stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Janus Henderson Group PLC, Patten Group Inc., Schroder Investment Management Group, Investec Asset Management LTD, Los Angeles Capital Management & Equity Research Inc., Point72 Asset Management L.P. and KBC Group NV. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.

How do I buy Celgene Corporation stock?

Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene Corporation's stock price today?

One share of Celgene Corporation stock can currently be purchased for approximately $104.50.

How big of a company is Celgene Corporation?

Celgene Corporation has a market capitalization of $82.79 billion and generates $11.23 billion in revenue each year. The biopharmaceutical company earns $2.00 billion in net income (profit) each year or $4.21 on an earnings per share basis. Celgene Corporation employs 7,132 workers across the globe.

How can I contact Celgene Corporation?

Celgene Corporation's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene Corporation (CELG)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  1,630 (Vote Outperform)
Underperform Votes:  468 (Vote Underperform)
Total Votes:  2,098
MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Celgene Corporation (NASDAQ:CELG)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.652.632.782.78
Ratings Breakdown: 1 Sell Rating(s)
12 Hold Rating(s)
19 Buy Rating(s)
2 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
22 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
24 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
24 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $139.97$148.26$147.19$139.19
Price Target Upside: 33.94% upside24.05% upside15.50% upside18.65% upside

Consensus Price Target History for Celgene Corporation (NASDAQ:CELG)

Price Target History for Celgene Corporation (NASDAQ:CELG)

Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/22/2017CannReiterated RatingBuy$166.00N/AView Rating Details
11/17/2017BMO Capital MarketsBoost Price TargetOutperform$148.00 -> $155.00N/AView Rating Details
11/16/2017Canaccord GenuitySet Price TargetBuy$140.00N/AView Rating Details
11/16/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$166.00N/AView Rating Details
11/3/2017MizuhoReiterated RatingBuyN/AView Rating Details
10/30/2017Cantor FitzgeraldReiterated RatingHold$112.00N/AView Rating Details
10/27/2017J P Morgan Chase & CoSet Price TargetBuy$123.00N/AView Rating Details
10/27/2017Barclays PLCReiterated RatingEqual Weight -> Equal Weight$135.00 -> $105.00N/AView Rating Details
10/27/2017Citigroup Inc.Lower Price TargetNeutral$140.00 -> $102.00N/AView Rating Details
10/27/2017SunTrust Banks, Inc.Lower Price TargetBuy -> Buy$156.00 -> $127.00N/AView Rating Details
10/27/2017Royal Bank Of CanadaLower Price TargetTop Pick$166.00 -> $148.00N/AView Rating Details
10/27/2017Goldman Sachs Group IncReiterated RatingSell$116.00 -> $91.00N/AView Rating Details
10/27/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
10/27/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingHold$103.00N/AView Rating Details
10/26/2017Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy -> Buy$160.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingNeutral -> Neutral$133.00N/AView Rating Details
10/22/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/20/2017Leerink SwannReiterated RatingBuy$156.00N/AView Rating Details
10/20/2017William BlairReiterated RatingOutperformN/AView Rating Details
10/20/2017Stifel NicolausLower Price TargetBuy$155.00 -> $149.00N/AView Rating Details
10/17/2017Sanford C. BernsteinInitiated CoverageOutperform$162.00N/AView Rating Details
10/16/2017Jefferies Group LLCReiterated RatingBuy$160.00N/AView Rating Details
9/13/2017Bank of America CorporationReiterated RatingBuyLowView Rating Details
9/12/2017Cowen IncReiterated RatingBuy$150.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
7/6/2017Credit Suisse GroupSet Price TargetBuy$148.00LowView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
4/28/2016Raymond James Financial, Inc.Reiterated RatingBuyN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralN/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Celgene Corporation (NASDAQ:CELG)

Earnings by Quarter for Celgene Corporation (NASDAQ:CELG)

Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018$1.94N/AView Earnings Details
10/26/2017Q3 2017$1.87$1.91$3.42 billion$3.29 billionViewN/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.23 billion$3.27 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celgene Corporation (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.61
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.44$1.46$1.45
Q2 20173$1.61$1.68$1.64
Q3 20173$1.68$1.81$1.73
Q4 20173$1.72$1.84$1.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene Corporation (NASDAQ:CELG)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ CELG)

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 79.48%
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Insider Trades by Quarter for Celgene Corporation (NASDAQ CELG)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017Terrie CurranInsiderSell1,727$143.89$248,498.03View SEC Filing  
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.00View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.50View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.12View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.00View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.00View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.00View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.80View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.50View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.30View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.00View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.39View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celgene Corporation (NASDAQ CELG)

Source:
DateHeadline
CAR-T Therapy Space 2017 Progress ReportCAR-T Therapy Space 2017 Progress Report
finance.yahoo.com - November 24 at 3:51 PM
Celgene Corporation (CELG) Receives Consensus Recommendation of "Buy" from BrokeragesCelgene Corporation (CELG) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 23 at 8:24 PM
Celgene Corporation (CELG) Stock Rating Reaffirmed by CannCelgene Corporation (CELG) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - November 23 at 7:20 PM
Celgene (CELG) Announces Results from 282 Abstracts Including its Therapies and Pipeline Compounds to Be Presented at ASHCelgene (CELG) Announces Results from 282 Abstracts Including its Therapies and Pipeline Compounds to Be Presented at ASH
www.streetinsider.com - November 22 at 10:49 PM
Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American ... - Business Wire (press release)Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American ... - Business Wire (press release)
www.businesswire.com - November 22 at 5:49 PM
Celgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in DecemberCelgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in December
finance.yahoo.com - November 21 at 5:15 PM
TheStreet Lowers Celgene Corporation (CELG) to C+TheStreet Lowers Celgene Corporation (CELG) to C+
www.americanbankingnews.com - November 21 at 4:06 PM
Celgene up 2% after would-be generic competitor misses deadline to file for Revlimid patent challengeCelgene up 2% after would-be generic competitor misses deadline to file for Revlimid patent challenge
seekingalpha.com - November 21 at 12:23 PM
Celgene Corporation Stock Is a Steal Right Now, Heres Why - Investorplace.comCelgene Corporation Stock Is a Steal Right Now, Here's Why - Investorplace.com
investorplace.com - November 21 at 5:21 AM
The Market Tells a Tale of Two GapsThe Market Tells a Tale of Two Gaps
finance.yahoo.com - November 20 at 6:13 PM
Celgene Corporation Stock Is a Steal Right Now, Here’s WhyCelgene Corporation Stock Is a Steal Right Now, Here’s Why
finance.yahoo.com - November 20 at 6:13 PM
Celgene (CELG) a Sell on Flagging Quant ScoreCelgene (CELG) a Sell on Flagging Quant Score
investorplace.com - November 20 at 2:51 PM
Celgene Corporation Stock Is a Steal Right Now, Here’s WhyCelgene Corporation Stock Is a Steal Right Now, Here’s Why
investorplace.com - November 20 at 2:15 PM
Celgene Corporation (CELG) Given a $140.00 Price Target at Canaccord GenuityCelgene Corporation (CELG) Given a $140.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - November 18 at 1:38 PM
Trade of the Day: Celgene Corporation Attempts a Breakout - Investorplace.comTrade of the Day: Celgene Corporation Attempts a Breakout - Investorplace.com
investorplace.com - November 18 at 8:32 AM
Celgene Corporation (CELG) Price Target Increased to $155.00 by Analysts at BMO Capital MarketsCelgene Corporation (CELG) Price Target Increased to $155.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - November 17 at 5:58 PM
Trade of the Day: Celgene Corporation Attempts a BreakoutTrade of the Day: Celgene Corporation Attempts a Breakout
investorplace.com - November 17 at 7:25 AM
BRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDABRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA
www.reuters.com - November 16 at 12:37 PM
Oppenheimer Holdings, Inc. Reiterates "$166.00" Price Target for Celgene Corporation (CELG)Oppenheimer Holdings, Inc. Reiterates "$166.00" Price Target for Celgene Corporation (CELG)
www.americanbankingnews.com - November 16 at 11:32 AM
Celgene whistleblower seeks dismissal of law firms lawsuitCelgene whistleblower seeks dismissal of law firm's lawsuit
www.reuters.com - November 15 at 12:33 AM
BeiGene Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)BeiGene Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 13 at 11:13 PM
A Rare Quarterly Appearance by bluebird bio Inc.'s ManagementA Rare Quarterly Appearance by bluebird bio Inc.'s Management
finance.yahoo.com - November 13 at 11:13 PM
ETFs with exposure to Celgene Corp. : November 13, 2017ETFs with exposure to Celgene Corp. : November 13, 2017
finance.yahoo.com - November 13 at 11:13 PM
Analysis of Quant Score Keep Celgene (CELG) a SellAnalysis of Quant Score Keep Celgene (CELG) a Sell
investorplace.com - November 13 at 3:03 PM
5 Irresistible Reasons to Buy Celgene Stock Right Now (Hint: 1 Is that It's Dirt Cheap)5 Irresistible Reasons to Buy Celgene Stock Right Now (Hint: 1 Is that It's Dirt Cheap)
finance.yahoo.com - November 12 at 4:55 PM
Wall Street dealmaking is heating up, but it's not a sign stocks are topping: NYSE traderWall Street dealmaking is heating up, but it's not a sign stocks are topping: NYSE trader
finance.yahoo.com - November 10 at 4:47 PM
What Investors Should Know About Celgene Corporation’s (CELG) Financial StrengthWhat Investors Should Know About Celgene Corporation’s (CELG) Financial Strength
finance.yahoo.com - November 10 at 4:47 PM
IYH, BMY, LLY, CELG: Large Outflows Detected at ETFIYH, BMY, LLY, CELG: Large Outflows Detected at ETF
www.nasdaq.com - November 9 at 7:56 PM
Due To Its Strong Growth Potential, Celgene Is Undervalued Right NowDue To Its Strong Growth Potential, Celgene Is Undervalued Right Now
seekingalpha.com - November 9 at 7:55 PM
How Celgene’s Abraxane Is Positioned after 3Q17How Celgene’s Abraxane Is Positioned after 3Q17
finance.yahoo.com - November 9 at 7:55 PM
Biotech Celgene Could Rebound By More Than 15%Biotech Celgene Could Rebound By More Than 15%
finance.yahoo.com - November 9 at 7:55 PM
Cramer's lightning round: You don't want to touch Pandora...Cramer's lightning round: You don't want to touch Pandora...
finance.yahoo.com - November 9 at 7:55 PM
Celgene Corporation (CELG) to Post FY2019 Earnings of $10.08 Per Share, Leerink Swann ForecastsCelgene Corporation (CELG) to Post FY2019 Earnings of $10.08 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - November 8 at 9:52 PM
5 Technical Levels Discussed On Wednesdays PreMarket Prep5 Technical Levels Discussed On Wednesday's PreMarket Prep
finance.yahoo.com - November 8 at 8:42 PM
How Did Celgene Perform in 3Q17?How Did Celgene Perform in 3Q17?
finance.yahoo.com - November 8 at 8:42 PM
How Celgene’s Revlimid and Pomalyst Are Positioned after 3Q17How Celgene’s Revlimid and Pomalyst Are Positioned after 3Q17
finance.yahoo.com - November 8 at 8:42 PM
How Celgene’s Otezla Is Positioned after 3Q17How Celgene’s Otezla Is Positioned after 3Q17
finance.yahoo.com - November 8 at 8:42 PM
Financial Analysis: Celgene Corporation (CELG) versus The CompetitionFinancial Analysis: Celgene Corporation (CELG) versus The Competition
www.americanbankingnews.com - November 8 at 2:08 PM
$3.46 Billion in Sales Expected for Celgene Corporation (CELG) This Quarter$3.46 Billion in Sales Expected for Celgene Corporation (CELG) This Quarter
www.americanbankingnews.com - November 8 at 9:33 AM
Cramer's lightning round: Don't give up on IncyteCramer's lightning round: Don't give up on Incyte
finance.yahoo.com - November 7 at 8:03 PM
Inferior Industry Group Rank Drop Celgene (CELG) to Sell - Investorplace.comInferior Industry Group Rank Drop Celgene (CELG) to Sell - Investorplace.com
investorplace.com - November 7 at 4:28 AM
Top Stock Reports for Facebook, Celgene & BlackRockTop Stock Reports for Facebook, Celgene & BlackRock
www.zacks.com - November 6 at 6:17 PM
 Analysts Expect Celgene Corporation (CELG) Will Post Earnings of $1.91 Per Share Analysts Expect Celgene Corporation (CELG) Will Post Earnings of $1.91 Per Share
www.americanbankingnews.com - November 6 at 5:24 PM
Inferior Industry Group Rank Drop Celgene (CELG) to SellInferior Industry Group Rank Drop Celgene (CELG) to Sell
investorplace.com - November 6 at 3:37 PM
Celgene Corporations (CELG) "Buy" Rating Reaffirmed at MizuhoCelgene Corporation's (CELG) "Buy" Rating Reaffirmed at Mizuho
www.americanbankingnews.com - November 4 at 1:32 PM
Biotech ETFs Struggle on Celgene Shock WavesBiotech ETFs Struggle on Celgene Shock Waves
www.nasdaq.com - November 4 at 7:56 AM
Celgene Corp. :CELG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017Celgene Corp. :CELG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017
finance.yahoo.com - November 4 at 7:56 AM
ETFs with exposure to Celgene Corp. : November 3, 2017ETFs with exposure to Celgene Corp. : November 3, 2017
finance.yahoo.com - November 4 at 7:55 AM
Why Celgene Crashed 30% in October -- and What Now?Why Celgene Crashed 30% in October -- and What Now?
www.fool.com - November 3 at 5:43 PM
Sharp Drop Celgene Corporation Stock May Have Just Created an ... - Investorplace.comSharp Drop Celgene Corporation Stock May Have Just Created an ... - Investorplace.com
investorplace.com - November 2 at 5:52 PM

Social Media

Financials

Chart

Celgene Corporation (NASDAQ CELG) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.